PHARMACOKINETICS OF CEFEPIME AFTER INTRAPERITONEAL ADMINISTRATION VIA CYCLER-THERAPY IN APD PATIENTS WITHOUT PERITONITIS

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509930-21-00

Acronym

Enrollment

Registered

2024-04-15

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD 5, Peritoneal Dialysis

Brief summary

AUC, Cmax, Half-life (t1/2), Time to reach maximum drug concentration (tmax)

Detailed description

Ratios of AUC and Cmax of different compartments, Time above the minimal inhibitory concentration T>MIC, Ratio of AUC from 0 to 24 hours (AUC 0-24)/MIC

Interventions

DRUGCefepim-MIP 1 g Pulver zur Herstellung einer Injektions- / Infusionslösung

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
AUC, Cmax, Half-life (t1/2), Time to reach maximum drug concentration (tmax)	—

Secondary

Measure	Time frame
Ratios of AUC and Cmax of different compartments, Time above the minimal inhibitory concentration T>MIC, Ratio of AUC from 0 to 24 hours (AUC 0-24)/MIC	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026